Pulse Oximetry and Oxygen Saturation Monitoring
Pulse oximetry is a non-invasive method for measuring the percentage of hemoglobin in arterial blood that is bound to oxygen, expressed as oxygen saturation (SpO₂). This page covers how the technology works, the clinical and home-based scenarios in which it is applied, the threshold values that guide clinical decision-making, and the limitations that affect accuracy across different patient populations. Understanding these boundaries is essential for anyone interpreting oximetry readings in pulmonary care, which is part of the broader regulatory and clinical framework governing pulmonary medicine.
Definition and Scope
Pulse oximetry measures SpO₂ — the estimated arterial oxygen saturation — by analyzing the differential absorption of red and infrared light by oxygenated hemoglobin (oxyhemoglobin) and deoxygenated hemoglobin. The result is expressed as a percentage, with a normal reference range of 95% to 100% in healthy adults at sea level, according to the American Thoracic Society (ATS).
The scope of pulse oximetry spans clinical environments (hospitals, intensive care units, surgical suites, outpatient clinics) and home monitoring settings. It is distinct from direct arterial measurement: SpO₂ is an estimation, while SaO₂ (arterial oxygen saturation) is measured from an arterial blood gas (ABG) sample drawn directly from arterial blood. SpO₂ and SaO₂ generally agree within 2 percentage points under ideal conditions, but this agreement degrades in specific physiological and technical circumstances.
Regulatory classification of pulse oximeters in the United States falls under the Food and Drug Administration (FDA) as Class II medical devices, subject to 21 CFR Part 880. The FDA issued a Safety Communication in 2021 specifically addressing the accuracy limitations of pulse oximeters, particularly their reduced performance in people with darker skin pigmentation — an issue that had been documented in peer-reviewed literature but had not previously been prominently communicated to the public.
How It Works
Pulse oximetry operates on the Beer-Lambert law of light absorption. Two wavelengths of light are emitted through a translucent tissue site — typically a fingertip, earlobe, or forehead — and the detector on the opposite side measures how much of each wavelength is absorbed.
- Red light (approximately 660 nm): Absorbed more strongly by deoxygenated hemoglobin.
- Infrared light (approximately 940 nm): Absorbed more strongly by oxygenated hemoglobin.
- Ratio calculation: The oximeter's processor computes the ratio of pulsatile (AC) to non-pulsatile (DC) components at each wavelength, isolating the arterial signal from venous blood, skin, and tissue.
- Calibration lookup: The ratio is cross-referenced against empirical calibration curves derived from studies of healthy volunteers across SpO₂ ranges typically from 70% to 100%.
- SpO₂ display: The result is displayed as a percentage, updated continuously (typically every 1–2 seconds in clinical-grade devices).
Perfusion index (PI), a related metric available on some devices, quantifies the strength of the pulsatile signal at the measurement site. A PI below 0.3% generally indicates a weak signal and reduces confidence in the SpO₂ reading.
Pulse oximeters do not detect carboxyhemoglobin (carbon monoxide bound to hemoglobin) or methemoglobin — both of which read as oxygenated hemoglobin on standard two-wavelength devices. Co-oximetry, performed on blood samples using devices with four or more wavelengths, is required to detect these dyshemoglobins. This distinction is clinically critical in cases of suspected carbon monoxide poisoning.
Common Scenarios
Pulse oximetry is applied across a wide spectrum of pulmonary and critical care situations. The pulmonary function tests and clinical evaluations described throughout pulmonary medicine resources on this site often incorporate oximetry as a baseline or continuous monitoring tool.
Inpatient and intensive care monitoring: Continuous SpO₂ monitoring is standard in mechanically ventilated patients, post-operative recovery, and in patients admitted with conditions including pulmonary embolism, pneumonia, and COPD exacerbations.
Titration of supplemental oxygen: Oximetry guides oxygen therapy dosing decisions. In COPD, clinical guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend targeting SpO₂ of 88–92% in patients at risk of hypercapnic respiratory failure, rather than the 94–98% target used in most other acutely ill adults.
Exercise and pulmonary rehabilitation: Oximetry during six-minute walk tests and pulmonary rehabilitation sessions identifies exercise-induced desaturation, defined as a sustained SpO₂ drop to below 88% during exertion.
Home monitoring in chronic disease: Patients with pulmonary fibrosis, pulmonary hypertension, and severe COPD may use home pulse oximeters to monitor stability or detect acute deterioration. The Centers for Medicare and Medicaid Services (CMS) includes nocturnal oximetry criteria in coverage determinations for home oxygen under Durable Medical Equipment (DME) benefit categories.
Sleep studies: Overnight oximetry is used as a screening tool for sleep apnea, measuring the oxygen desaturation index (ODI) — the number of desaturation events of ≥3% or ≥4% per hour of recording.
Decision Boundaries
Clinical thresholds for SpO₂ vary by condition and guideline source. The following structured breakdown reflects established reference ranges from ATS, GOLD, and published critical care literature:
| SpO₂ Range | Clinical Interpretation |
|---|---|
| 95–100% | Normal in healthy adults at sea level |
| 92–94% | Low-normal; warrants clinical assessment in context |
| 88–91% | Clinically significant hypoxemia; supplemental oxygen generally indicated |
| Below 88% | Threshold for CMS home oxygen qualification; associated with increased mortality risk in COPD |
| Below 85% | Severe hypoxemia; accuracy of pulse oximetry degrades at this level |
The FDA's 2021 Safety Communication confirmed that standard pulse oximeters can overestimate SpO₂ by 2–4 percentage points in individuals with higher melanin concentrations, meaning a displayed reading of 92% may reflect a true arterial saturation near 88%–90%. This finding has prompted ongoing review by the FDA's Digital Health Center of Excellence and prompted the National Institutes of Health (NIH) to fund research specifically on oximetry equity.
When SpO₂ results conflict with clinical presentation — a patient appearing cyanotic with a displayed SpO₂ of 94%, for example — ABG measurement is the definitive next step. SpO₂ is a screening and monitoring tool; it does not replace direct biochemical measurement of oxygenation status in ambiguous or high-stakes clinical situations.
References
- American Thoracic Society (ATS)
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) — GOLD 2023 Report
- U.S. Food and Drug Administration — Pulse Oximeter Accuracy and Limitations: FDA Safety Communication (2021)
- U.S. Food and Drug Administration — 21 CFR Part 880 (Medical Devices)
- Centers for Medicare and Medicaid Services (CMS) — Durable Medical Equipment Coverage
- National Institutes of Health (NIH)
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)